Salipro Biotech Signed a Research Collaboration and License Agreement with Sanofi to Advance Discovery Programs
Shots:
- The companies collaborated to discover therapeutics biologics against a drug target with therapeutic properties by combining both the company’s expertise i.e., Salipro Biotech's expertise of developing a stable Ag of GPCRs, ion channels & transporters by using its Salipro platform with Sanofi’s discovery programs
- Salipro technology is designed to stabilize membrane proteins in native forms to use membrane proteins in drug discovery programs for therapeutic Abs, small molecule drugs & structure-based drug design
- For the advancement of drug discovery efforts against a selected membrane protein drug target, Salipro works with Sanofi’s team. Additionally, Salipro entered into multiple research collaborations with pharma & biotech companies
Ref: PRNewswire | Image: Sanofi
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
